-
1.发明授权DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS 有权DIARYLAMINHALTIGE化合物和组合物及其作为C-KIT受体调节剂
公开(公告)号：EP1928236B1
公开(公告)日：2011-11-23
申请号：EP06815653.8
申请日：2006-09-26
申请人： IRM LLC , Novartis AG
发明人： MOLTENI, Valentina , LI, Xiaolin , CHIANELLI, Donatella , LOREN, Jon , LIU, Yi , KARANEWSKY, Donald, S. , FURET, Pascal , GUAGNANO, Vito , YOU, Shuli , NABAKKA, Juliet , LIU, Xiaodong , PAN, Shifeng
CPC分类号： C07D403/04 , C07D239/42 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/04 , C07D413/12 , C07D417/12 , C07D471/04 , C07D491/10
摘要： Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
-
公开(公告)号：EP2079729A1
公开(公告)日：2009-07-22
申请号：EP07844851.1
申请日：2007-11-02
申请人： IRM LLC , NOVARTIS AG
发明人： CHIANELLI, Donatella , LI, Xiaolin , LIU, Xiaodong , LOREN, Jon , MOLTENI, Valentina , NABAKKA, Juliet , REVESZ, Laszlo , PEREZ, Lawrence B. , BROOKS, Clinton , WRONA, Wojciech , MANLEY, Paul W. , BREITENSTEIN, Werner
IPC分类号： C07D401/14 , C07D403/12 , C07D405/14 , C07D407/14 , C07D413/14 , C07D417/14 , C07D471/04 , A61K31/506 , A61P33/06 , A61P25/00 , A61P35/00
CPC分类号： C07D401/14 , C07D401/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to beat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases. Formula (I).
摘要翻译： 本发明提供了一类新化合物，包含此类化合物的药物组合物以及使用这些化合物来击败或预防与异常或失调的激酶活性相关的疾病或病症，特别是涉及c-kit，PDGFRα和PDGFRα异常活化的疾病或病症 PDGFRβ激酶。 公式（I）。
-
3.发明公开
公开(公告)号：EP2152688A1
公开(公告)日：2010-02-17
申请号：EP08747596.8
申请日：2008-05-02
申请人： IRM LLC , Novartis AG , Li, Xiaolin , Liu, Xiaodong , Molteni, Valentina , Chianelli, Donatella , Loren, Jon , Nabakka, Juliet
发明人： LI, Xiaolin , LIU, Xiaodong , MOLTENI, Valentina , CHIANELLI, Donatella , LOREN, Jon , NABAKKA, Juliet , RAMSEY, Timothy , BREITENSTEIN, Werner
IPC分类号： C07D401/04 , C07D417/14 , A61K31/506 , A61P35/00 , A61P37/00
CPC分类号： C07D401/04 , C07D417/14
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR and PDGFR kinases.
摘要翻译： 本发明提供了一类新化合物，包含此类化合物的药物组合物以及使用此类化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症，特别是涉及c-kit，PDGFR和PDGFR异常活化的疾病或病症的方法 PDGFR激酶。
-
4.发明公开DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS 有权DIARYLAMINHALTIGE化合物和组合物及其作为C-KIT受体调节剂
公开(公告)号：EP1928236A2
公开(公告)日：2008-06-11
申请号：EP06815653.8
申请日：2006-09-26
申请人： IRM, LLC , Novartis AG
发明人： MOLTENI, Valentina , LI, Xiaolin , CHIANELLI, Donatella , LOREN, Jon , LIU, Yi , KARANEWSKY, Donald, S. , FURET, Pascal , GUAGNANO, Vito , YOU, Shuli , NABAKKA, Juliet , LIU, Xiaodong , PAN, Shifeng
CPC分类号： C07D403/04 , C07D239/42 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/04 , C07D413/12 , C07D417/12 , C07D471/04 , C07D491/10
摘要： Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
-
公开(公告)号：EP2751104A1
公开(公告)日：2014-07-09
申请号：EP12756885.5
申请日：2012-08-29
申请人： IRM LLC
发明人： MOLTENI, Valentina , PETRASSI, Hank Michael James , LI, Xiaolin , LIU, Xiaodong , LOREN, Jon , NABAKKA, Juliet , NGUYEN, Bao , YEH, Vince
IPC分类号： C07D471/04 , A61K31/437 , A61P3/00 , A61P17/00 , A61P11/00 , A61P29/00
CPC分类号： C07D491/107 , C07D471/04 , C07D491/044 , C07D491/048 , C07D498/04
摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRalpha, PDGFRbeta) kinases.
摘要翻译： 本发明提供了用作蛋白激酶抑制剂的式（I）和（II）的化合物及其药物组合物，以及使用这些化合物治疗，改善或预防与异常或失调的激酶活性相关的病症的方法。 在一些实施方案中，本发明提供了使用此类化合物来治疗，改善或预防涉及c-kit或c-kit和PDGFR（PDGFRα，PDGFRβ）激酶的异常活化的疾病或病症的方法。
-
6.发明授权HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS 有权杂环化合物和组合物中作为c-kit和PDGFR激酶抑制剂
公开(公告)号：EP2252612B1
公开(公告)日：2012-03-28
申请号：EP09711557.0
申请日：2009-02-20
申请人： IRM LLC
发明人： LI, Xiaolin , LIU, Xiaodong , LOREN, Jon , MOLTENI, Valentina , NABAKKA, Juliet , YEH, Vince , CHIANELLI, Donatella
IPC分类号： C07D471/04 , A61K31/4375 , A61P29/00 , A61P35/00 , A61P37/00 , A61P25/00 , A61P9/00
CPC分类号： C07D471/04
摘要： The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.
-
公开(公告)号：EP2751105A1
公开(公告)日：2014-07-09
申请号：EP12762445.0
申请日：2012-08-29
申请人： IRM LLC
发明人： LOREN, Jon , LI, Xiaolin , LIU, Xiaodong , MOLTENI, Valentina , NABAKKA, Juliet , NGUYEN, Bao , PETRASSI, Hank Michael James , YEH, Vince , RUCKER, Paul Vincent
IPC分类号： C07D471/04 , A61K31/437 , A61P11/06
CPC分类号： C07D471/04
摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.
-
8.发明公开IMIDAZO [1, 2]PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS 审中-公开咪唑并[1,2]哒嗪化合物和组合物AS TRK抑制剂
公开(公告)号：EP2614062A1
公开(公告)日：2013-07-17
申请号：EP11758063.9
申请日：2011-09-09
申请人： IRM LLC
发明人： FAN, Yi , LOREN, Jon , MOLTENI, Valentina , ALBAUGH, Pamela A. , CHOPIUK, Gregory , SMITH, Jeffrey M. , FLATT, Brenton T.
IPC分类号： C07D471/04 , C07D487/04 , A61K31/4353 , A61K31/4985 , A61P37/00
CPC分类号： C07D471/04 , C07D487/04
摘要： The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.
-
9.发明公开
公开(公告)号：EP2076513A1
公开(公告)日：2009-07-08
申请号：EP07844322.3
申请日：2007-10-16
申请人： IRM LLC
发明人： CHIANELLI, Donatella , COW, Christopher , HE, Yun , JIANG, Songchun , LI, Xiaolin , LIU, Xiaodong , LIU, Zuosheng , LOREN, Jon , MOLTENI, Valentina , NABAKKA, Juliet , REN, Pingda , SIM, Taebo , WANG, Xiaodong , YOU, Shuli
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR , PDGFR , CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF , SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2 , BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.
-
公开(公告)号：EP2751107A1
公开(公告)日：2014-07-09
申请号：EP12766749.1
申请日：2012-08-31
发明人： LIANG, Fang , GIBNEY, Michael , YEH, Vince , LI, Xiaolin , MOLTENI, Valentina , SHAW, Duncan , BERMAN, Ashley Mitchell , LEWIS, Sarah , LOREN, Jon , FURMINGER, Vikki
IPC分类号： C07D471/04 , A61K31/437 , A61P37/00
CPC分类号： C07D471/04
摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of PDGFR (PDGFRα, PDGFRβ) kinases or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.015 秒)
